Earlier this year, the pharma company confirmed that its GLP-1 focused drug, currently just called PF-08653944, is performing very well in Phase 2b trials
For example, emerging research on GLP-1 receptor agonistssuch as liraglutide and semaglutidehas already demonstrated promising cognitive improvements, enhanced memory, and protection against neurodegenerative changes
risk reduction Practical Approach Prioritize safe continuation of scheduled procedures for patients on GLP-1RAs, applying similar risk management as for other patients with gastroparesis
Pharmaceutical-grade semaglutide and tirzepatide from FDA-approved manufacturers have rigorous quality controls, consistent potency, and verified purity
These wipes must meet the strictest standards for particle release and bioburden